Background: High circulating insulin-like growth factor-I (IGF-I) concentrations have been associated with increased risk for prostate cancer in several prospective epidemiological studies. In this study, we investigate the association between circulating IGF-I concentration and risk of prostate cancer over the long term in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
Introduction
Insulin-like growth factor (IGF-I), a polypeptide with mitotic and antiapoptotic effects (1) , is associated with an increased risk for prostate cancer, as shown in a pooled reanalysis of worldwide prospective data based on 3,700 men with prostate cancer and 5,200 controls (2) . However, most of the cases in this collaborative reanalysis were diagnosed within 6 years of blood collection, limiting the ability to investigate heterogeneity in risk by length of follow-up and leaving open the possibility of reverse causality (whereby, before diagnosis, a developing prostate cancer causes alterations in circulating IGF-I concentration).
In the European Prospective Investigation into Cancer and Nutrition (EPIC), we previously reported a marginally significant increased prostate cancer risk for men in the highest versus lowest third of IGF-I concentration [OR 1.35; 95% confidence interval (CI) 0.99-1.82; P trend ¼ 0.08]. These results were on the basis of 630 cases (and 630 controls), with a median time from blood collection to diagnosis of 3.4 years (range, 0.1-8.5 years; ref. 3) . We report here results from an extension of this work, including a total of 1,542 prostate cancer cases (matched to 1,542 control men) diagnosed a median of 5.8 years after blood collection, with approximately 35% of cases diagnosed more than 7 years after blood collection.
Materials and Methods

Study population
The methods of recruitment used in the EPIC study have been described previously (4) . In brief, between 1992 and 2000, approximately 360,500 women and 153,400 men were recruited from 23 centers in 10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). All participants completed either a standardized food-frequency questionnaire or an interview-based dietary questionnaire, and a detailed lifestyle questionnaire. Approximately 385,700 participants (of which 139,600 were men) provided a blood sample. All participants provided written informed consent and local ethics committees in the participating countries and the Internal Review Board of the International Agency for Cancer Research (IARC) approved the study.
The standardized blood collection protocol involved transportation of whole blood in the collection syringe to a local laboratory where samples were processed and separated into serum, plasma, red cells, and buffy coat fractions within 24 hours of collection, before placement in 0.5-mL straws for storage at À196 C in liquid nitrogen tanks. Variation to the standardized procedure occurred in the following centers: in the Oxford cohort (UK), samples were sent in the post at ambient temperature to a laboratory in Norfolk (UK), with an average transit time of 1.5 days; in the Copenhagen cohort (Denmark), samples were stored in 1 mL tubes in nitrogen vapor at À150 C, and in the Umea cohort (Sweden), EDTA plasma (rather than serum) samples were archived and stored at À80 C in electric freezers.
Follow-up for cancer incidence and vital status
Follow-up and case identification was provided through record linkage with population-based cancer registries in Denmark, Italy, the Netherlands, Spain, Sweden, and the United Kingdom. In Germany and Greece, active follow-up was achieved through contact with study participants and their next of kin and verified through health insurance or medical records and cancer and pathology registries or reports. Selection of case and control participants from the study cohort
Cases were defined as men who developed prostate cancer after the date of blood collection and before the end of the study period, as determined by the latest date of follow-up in each study center. Among participants who had completed a lifestyle and dietary questionnaire, provided a blood sample at recruitment, and had no previous cancer diagnosis, 1,874 were diagnosed with incident prostate cancer during the follow-up period. An incidence density sampling protocol was used to select control participants at random from the cohort of men who were alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case and who were matched on study center, length of follow-up, age at blood collection (þ/À 6 months), time of blood collection (þ/À 1 hour) and duration of fasting at blood collection (< 3, 3-6, >6 hours). Blood samples were available for 1,711 of the 1,874 identified cases, and after exclusion of incomplete case-control sets, 1,542 prostate cancer cases, and 1,542 matched controls were available for analysis. This number includes 630 prostate cancer cases from an earlier study (phase I) and an additional 912 cases with a later diagnosis (phase II).
Tumor stage information [tumor-node-metastasis (TNM) staging code], derived from pathology reports and cancer registry data, was used to define the following categories: localized (T0 or T1 or T2 and N0 or NX and M0,  or 
Laboratory analysis
Serum samples from phase I of the study were assayed in singleton at IARC, Lyon (France) using the DSL-10-5600 ACTIVE ELISA from Diagnostic Systems Laboratories (DSL) as previously reported (3). Serum samples from phase II were assayed in duplicate at the Cancer Epidemiology Unit (CEU) laboratory in Oxford (UK) using the DSL-10-5600 ACTIVE ELISA from DSL, with the exception of plasma samples from Sweden, which were analyzed in singleton by using the automated IDS-iSYS immunoassay system from Immunodiagnostic Systems (IDS) Ltd. Both assays included a step to dissociate IGF-I from IGF-I-binding proteins before measurement. A comparison of 20 samples measured using both the DSL-10-5600 ACTIVE ELISA and the IDS-iSYS showed relative agreement (r ¼ 0.99), although IGF-I concentrations were on average 23% lower in the IDS-iSYS assay than the DSL-10-5600 ACTIVE ELISA. The lower limit of detection was <1 nmol/L for the DSL-10-5600 ACTIVE ELISA and 1.3 nmol/L for the IDS-iSYS immunoassay, adequate to detect the lowest concentration in all study samples.
Laboratory personnel were blind to the case-control status of the samples and each case-control set was analyzed in the same batch, together with duplicate quality control samples. For the DSL-10-5600 ACTIVE ELISA assay, the mean intra-and interbatch coefficients of variation were 3% and 13% for phase I samples and 4.4% and 12.4% for phase II samples, respectively; for the IDS-iSYS immunoassay the mean intra-and interbatch coefficients of variation were 2.3% and 3.2% for phase II samples (from Sweden only).
Statistical analysis
Differences in baseline characteristics of case and control participants in matched sets were compared using paired-sample t tests for continuous variables and conditional logistic regression for categorical variables. Logarithmic transformation of IGF-I values was conducted to approximate a normal distribution and box and whisker plots and letter-value displays were used to examine the distribution and to identify possible outliers. Exclusion of observations identified as severe outliers on the logarithmic scale (>3 times the interquartile range; N ¼ 4) made no material difference to the risk estimates and therefore all observations were included in the final models.
Analysis of variance was used to examine heterogeneity in the geometric mean IGF-I concentration amongst controls by the following variables: phase of study (phase I, phase II), country (8) , age at blood collection ( 54, 55-59, 60-64, !65 years), height (quintiles), weight (quintiles), body mass index (BMI; <24.4, 24.4-26.3, 26.4-28.6, ! 28.7 kg/m 2 ), smoking (never, past, current, unknown), alcohol consumption (<8, 8-15, 16-39, !40 g/d, unknown), physical activity (inactive, moderately inactive, active, unknown), marital status (married/cohabitating, not married/cohabitating, unknown), and educational attainment (primary or equivalent, secondary, degree level, unknown). Where appropriate, adjustment was made for center, age at blood collection, alcohol consumption, educational attainment, BMI, and assay batch.
Conditional logistic regression models were used to calculate the ORs for prostate cancer risk by fourths of IGF-I concentration and for a doubling (log2 scale) in IGF-I concentration. Quartile cutoff points were defined by the distribution of values among the controls for all cohorts combined with the exception of Sweden, where countryspecific cutoff points were used to account for the differences in absolute concentrations attributable to the IDSiSYS immunoassay. Likelihood ratio c 2 tests for linear trend were obtained by replacing the quartiles with the logarithm of IGF-I as a continuous variable in the model.
The effects of potential confounding variables (other than those accounted for in the matched design) were examined by including additional regression terms in the conditional logistic regression model. Adjustment for height, weight, smoking, alcohol consumption, physical activity, marital status, and educational attainment made little difference to the risk estimates or their 95% confidence intervals (<10% change). However, all final models included adjustment for age at blood collection to ensure close comparability within matched sets. Separate sensitivity analyses were conducted that excluded the Umea (Sweden) cohort (because of the different assay used for these samples), and that excluded the first 4 years of follow-up.
Likelihood ratio c 2 tests (on the basis of the difference between the c 2 values from models with and without an interaction term between the linear trend variable and the factor of interest, e.g., stage of disease) were used to examine heterogeneity of linear-trend relative risk estimates for prostate cancer associated with the logarithm of IGF-I concentration by prostate cancer stage (localized, advanced), grade (low, high), time between blood collection and diagnosis (<4, 4-7, >7 years), age at diagnosis (<65, !65 years), age at blood collection (<60, !60 years), laboratory assay (DSL-10-5600 ACTIVE ELISA, IDS-iSYS), country (including countries grouped according to a North/South latitude (i.e., Northern countries defined as Denmark, Germany, the Netherlands, Sweden, and the UK, and Southern countries defined as Greece, Italy, and Spain)], and BMI (<25, !25 kg/m 2 ). Owing to the use of incidence density sampling for the selection of controls, the ORs presented approximate the incidence rate ratios for IGF-I in relation to prostate cancer in the study cohort (5) . All statistical analyses were conducted using Stata Statistical Software: Release 12 (StataCorp LP) and 2-tailed tests of statistical significance with P values below 0.05 were considered significant.
Results
IGF-I measurements were available for 1,542 matched case-control sets: 630 from phase I and 912 from phase II. Of these, 152 were from Denmark, 383 from Germany, 40 from Greece, 145 from Italy, 50 from the Netherlands, 200 from Spain, 192 from Sweden, and 380 from the United Kingdom. The mean age at diagnosis was 65.3 years (SD, 6.5) and the median time between blood collection and diagnosis was 5.8 years (range, 1 month-12.8 years). As shown in Table 1 , there were no significant differences between cases and controls according to height, BMI, smoking status, alcohol consumption, physical activity, marital status, and educational attainment. However, cases were on average slightly older at blood collection (60.12 vs. 60.10 years; P ¼ 0.03) and lighter (79.8 vs. 80.6 kg; P ¼ 0.04) than controls. The geometric mean IGF-I concentration was 3.8% higher in cases than in controls (20.5 vs. 19.8 nmol/L; P ¼ 0.001). Amongst the cases with information on stage and grade of disease, there was no evidence of heterogeneity by phase of study in the proportion of cases diagnosed with localized or advanced stage disease or in the proportion of cases classified as low-or high-grade disease ( Table 1) .
The geometric mean IGF-I concentrations according to baseline characteristics amongst the controls, with adjustment for center, age at blood collection, alcohol intake, educational attainment, BMI and batch, are shown in Table 2 . IGF-I concentration was lower in older men (P trend <0.0001) and higher in taller (P trend ¼ 0.01) and more educated men (P trend ¼ 0.01). There was significant heterogeneity in IGF-I concentration by assay for the IDS-iSYS assay used for Umea (Sweden) and DSL-10-5600 ACTIVE ELISA assay used for all other centers (P heterogeneity <0.0001), and by country (among those assayed using the DSL-10-5600 ACTIVE ELISA), being lowest in Greece (19.5 nmol/L), and highest in the Netherlands (22.8 nmol/L; P heterogeneity ¼ 0.002). There was also evidence of heterogeneity in IGF-I concentration by alcohol consumption (P heterogeneity ¼ 0.01), weight (P heterogeneity ¼ 0.01), and BMI (P heterogeneity ¼ 0.003), although there was no evidence of a trend for these variables (P trend ¼ 0.08, P trend ¼ 0.40, and P trend ¼ 0.34, respectively). IGF-I concentration did not vary according to smoking status or physical activity. Table 3 shows that IGF-I concentration was significantly associated with an increased risk of prostate cancer overall. In comparison to the lowest fourth, the risk of prostate cancer in the highest fourth of IGF-I concentration was 1.69 (95% CI: 1.35, 2.13; P trend ¼ 0.0002) after adjusting for age at blood collection. Further adjustment for height, weight, smoking, alcohol intake, marital status, physical activity, and educational attainment made little difference to the risk estimate (OR 1.72; 95% CI: 1.36, 2.17; P trend ¼ 0.0001; results not shown in table). The OR associated with a doubling of IGF-I concentration was 1.38 (95% CI: 1.17, 1.64; P trend ¼ 0.0002).
The associations between IGF-I concentration and risk for prostate cancer subdivided by case participant characteristics are also shown in Table 3 . Higher IGF-I was associated with increased risk for prostate cancer in all subgroups, with the exception of high-grade disease. Nonetheless, there was no significant heterogeneity between low-and high-grade diseases in the estimates of linear trends in relative risks. Furthermore, the positive association of higher circulating IGF-I with prostate cancer risk did not differ according to duration of follow-up [ORs for highest vs. lowest quartile for cancer diagnosis <4, 4-7, and >7 years after blood collection were 2.01 (1.35-2.99), 1.37 (0.94-2.00), and 1.80 (1.17-2.77), respectively (P heterogeneity ¼ 0.77)] or by any other subgroup examined, including stage of disease, age at diagnosis, age at blood collection, assay type, country (including countries grouped according to a North/South latitude), or BMI (P heterogeneity !0.05).
There was no evidence of heterogeneity in the trend for the association of IGF-I and risk for prostate cancer between the Umea cohort (Sweden) and the other centers (P heterogeneity ¼ 0.46) and exclusion of case-control sets from Umea changed the risk estimate by less than 10%.
Discussion
Our finding that a relatively high concentration of IGF-I is associated with an increased risk for prostate cancer is consistent with results from a pooled reanalysis of individual participant data from 12 prospective studies (which includes phase I of this study; ref.
2). This association is evident for both localized and advanced disease and exists over the short and long term. While it is likely that some men with subclinical disease at recruitment were included in our study [because of the long lag time between disease onset and clinical symptoms (6)], the positive association observed among men diagnosed with advanced stage disease (for whom nearly 65% were diagnosed more than 4 years after recruitment) and among men diagnosed more than 7 years after blood collection, supports the hypothesis that IGF-I is associated with prostate cancer many years before diagnosis.
IGF-I concentration was also associated with an increased risk of localized prostate cancer. This finding contrasts with those from ProtecT, a large case-control study of approximately 3,000 cases and 3,000 controls in the United Kingdom, which found no association between total IGF-I concentration and the risk for PSA (prostate specific antigen)-detected prostate cancer (7). As there is no formal screening program for prostate cancer in the countries included in the EPIC study, our cases comprise a mixture of PSA-detected and clinically detected disease, and it is possible that the differences between our results and those from ProtecT [and other studies of PSA-detected prostate cancer (7)] reflect Table 1 . Characteristics of 1,542 prostate cancer cases and 1,542 control subjects in EPIC overall and subdivided into study phase (Continued on the following page) biological differences in the association of IGF-I with PSA-detected and clinically relevant disease. Our finding that the association between higher IGF-I concentration and prostate cancer risk did not differ significantly by cancer stage is consistent with results from the pooled reanalysis (2) and supports a role for IGF-I in the development of prostate cancer, conceivably via established mitogenic and antiapoptotic mechanisms (1). There was no significant difference in the association of IGF-I with prostate cancer by grade of disease, although the risk appeared to be restricted to low-grade disease, with no association for high-grade disease, which is also consistent with the pooled reanalysis (2) and more recent findings from a large prospective study (8) . However, these results should be interpreted with caution because of small numbers of cases in the high-grade subgroup and the potential for misclassification error because of changes in grading practices over time (9) (10) (11) that may obscure the distinction between low-and high-grade diseases.
Strengths of this study are the prospective nature of the design, the moderately long length of follow-up and large sample size that meant that the subgroup investigations were, in most instances, adequately powered to detect modest risk estimates. The association between IGF-I and risk for prostate cancer remained significant after excluding the first 4 years of follow-up (thereby reducing the possibility of reverse causality) and the subcohort with deviations from the standardized assay method. There was minimal laboratory measurement error and the distribution of our IGF-I values amongst controls is comparable with that from other studies in healthy male adults (7, 12) . Previous studies have shown relatively high within-individual reproducibility for IGF-I measured in 2 samples collected up to 5 years apart [Spearman rank correlations of 0.7 (13), 0.66 (14) , and 0.87 (15) ]; however, measurement error and attenuation of risk estimates associated with a single sample would suggest that the true association per increment increase in IGF-I concentration with prostate cancer risk may be substantially stronger than that observed in our study.
Comparisons of these findings on the basis of men of white European origin with those in other ethnic groups are difficult to interpret as studies in Asian and AfricanAmerican populations have been too small to detect modest risk estimates (16, 17) . We did not measure IGF-I-binding proteins (IGFBP) in our extended study and although they are known to influence the bioavailability of IGF-I (18), there is evidence to suggest that the association between IGF-I concentration and risk for prostate cancer is not materially affected by adjustment for IGFBP-3, the major IGF-I-binding protein in the circulation (2) . The extent to which circulating IGF-I concentrations [influenced by anthropometric, diet, and lifestyle factors (19) (20) (21) (22) ] reflect activity at the tissue level is difficult to determine, as the bioavailability of IGF-I is modulated by interactions between growth hormone, insulin, IGFBPs, and IGF-I receptors (18, 23) . In future, investigation of the association between circulating IGF-I concentrations and expression of biomarkers at the tissue level may determine further the nature of the association of IGF-I with prostate cancer risk. Moreover, information from studies in a younger population is needed to determine the impact of long-term exposure to IGF-I levels and to elucidate the most important time period of IGF-I exposure in relation to prostate cancer development.
In conclusion, our results suggest that circulating concentrations of IGF-I in middle to late adulthood are Unknown for some participants; number of unknowns calculated by subtracting the known total number in each group from 1,542. c P value refers to tests of heterogeneity between the logarithm of the geometric means in the separate categories (excluding unknowns) calculated by using analysis of variance. 
